Evidence map›Paper›PMID 34668147›Full record

ReviewNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2021

Cannabinoids: an Effective Treatment for Chemotherapy-Induced Peripheral Neurotoxicity?

Guido Cavaletti, Paola Marmiroli, Cynthia L Renn, Susan G Dorsey, Maria Pina Serra, Marina Quartu, Cristina Meregalli

Open access · hybridAbstract readReview
In one paragraph

Review in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Article
  3. Chronic Pain in the Cancer Survivor.Current pain and headache reports · 2025
    Review
  4. Notoginsenoside R1, a Metabolite fromMolecules (Basel, Switzerland) · 2025
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Guido CavalettiExperimental Neurology Unit, School of Medicine and Surgery, University of Milano Bicocca, via Cadore 48, Monza, Italy. guido.cavaletti@unimib.it.
Paola MarmiroliDepartment of Biotechnology and Biosciences, University of Milano-Bicocca, Piazza della Scienza, 2, Milano, Italy.
Cynthia L RennDepartment of Pain and Translational Science, School of Nursing, University of Maryland, 655 West Lombard Street, Baltimore, MD, 21201, USA.
Susan G DorseyDepartment of Pain and Translational Science, School of Nursing, University of Maryland, 655 West Lombard Street, Baltimore, MD, 21201, USA.
Maria Pina SerraDepartment of Biomedical Sciences, University of Cagliari, Cittadella Universitaria, 09042, Monserrato, Italy.
Marina QuartuDepartment of Biomedical Sciences, University of Cagliari, Cittadella Universitaria, 09042, Monserrato, Italy.
Cristina MeregalliExperimental Neurology Unit, School of Medicine and Surgery, University of Milano Bicocca, via Cadore 48, Monza, Italy.
University of Milano-Bicocca · ITUniversity of Cagliari · ITUniversity of Maryland, Baltimore · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chemotherapy-induced peripheral neurotoxicity (CIPN) is one of the most frequent side effects of antineoplastic treatment, particularly of lung, breast, prostate, gastrointestinal, and germinal cancers, as well as of different forms of leukemia, lymphoma, and multiple myeloma. Currently, no effective therapies are available for CIPN prevention, and symptomatic treatment is frequently ineffective; thus, several clinical trials are addressing this unmet clinical need. Among possible pharmacological treatments of CIPN, modulation of the endocannabinoid system might be particularly promising, especially in those CIPN types where analgesia and neuroinflammation modulation might be beneficial. In fact, several clinical trials are ongoing with the specific aim to better investigate the changes in endocannabinoid levels induced by systemic chemotherapy and the possible role of endocannabinoid system modulation to provide relief from CIPN symptoms, a hypothesis supported by preclinical evidence but never consistently demonstrated in patients. Interestingly, endocannabinoid system modulation might be one of the mechanisms at the basis of the reported efficacy of exercise and physical therapy in CIPN patients. This possible virtuous interplay will be discussed in this review.

Indexed as

Antineoplastic AgentsCannabinoidsNeurotoxicity SyndromesPeripheral Nervous System DiseasesHumansMaleTreatment OutcomeAntineoplastic AgentsCannabinoidsCannabinoid receptorsChemotherapyEndocannabinoid systemNeuropathyTreatment

Identifiers

PMID34668147
PMCPMC8804126
OpenAlexW3164294749

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.